牛牛AI助理已提取核心訊息
Avenue Therapeutics, Inc. has filed a prospectus related to the resale of 33,080,598 shares of common stock by selling stockholders. These shares are comprised of Series A and Series B Warrant Shares, which were issued in a private placement that closed on January 9, 2024. The selling stockholders may sell these shares at any time through various methods such as open market transactions or private sales. The proceeds from the sale of the shares will go directly to the selling stockholders, and Avenue Therapeutics will not receive any proceeds from these sales. However, the company will receive proceeds from any cash exercise of the warrants. The common stock is listed on The Nasdaq Capital Market under the symbol 'ATXI.' The last reported sale price of Avenue Therapeutics' common stock was $0.15 per share as of January 31, 2024. The prospectus also includes information on the risks involved in investing in the securities and states that the SEC has not approved or disapproved the securities, nor have they passed upon the accuracy or adequacy of the prospectus.
Avenue Therapeutics, Inc. has filed a prospectus related to the resale of 33,080,598 shares of common stock by selling stockholders. These shares are comprised of Series A and Series B Warrant Shares, which were issued in a private placement that closed on January 9, 2024. The selling stockholders may sell these shares at any time through various methods such as open market transactions or private sales. The proceeds from the sale of the shares will go directly to the selling stockholders, and Avenue Therapeutics will not receive any proceeds from these sales. However, the company will receive proceeds from any cash exercise of the warrants. The common stock is listed on The Nasdaq Capital Market under the symbol 'ATXI.' The last reported sale price of Avenue Therapeutics' common stock was $0.15 per share as of January 31, 2024. The prospectus also includes information on the risks involved in investing in the securities and states that the SEC has not approved or disapproved the securities, nor have they passed upon the accuracy or adequacy of the prospectus.
Avenue Therapeutics, Inc.已提交了一份招股說明書，內容涉及出售股東轉售33,080,598股普通股。這些股票由A系列和B系列認股權證組成，這些認股權證以私募方式發行，於2024年1月9日結束。賣出股東可以隨時通過公開市場交易或私人銷售等各種方法出售這些股票。出售股票的收益將直接捐給出售股東，而Avenue Therapeutics不會從這些出售中獲得任何收益。但是，該公司將從認股權證的任何現金行使中獲得收益。普通股在納斯達克資本市場上市，股票代碼爲 “ATXI”。截至2024年1月31日，Avenue Therapeutics上次公佈的普通股銷售價格爲每股0.15美元。招股說明書還包括有關證券投資所涉風險的信息，並指出美國證券交易委員會沒有批准或不批准這些證券，也沒有透露招股說明書的準確性或充分性。
Avenue Therapeutics, Inc.已提交了一份招股說明書，內容涉及出售股東轉售33,080,598股普通股。這些股票由A系列和B系列認股權證組成，這些認股權證以私募方式發行，於2024年1月9日結束。賣出股東可以隨時通過公開市場交易或私人銷售等各種方法出售這些股票。出售股票的收益將直接捐給出售股東，而Avenue Therapeutics不會從這些出售中獲得任何收益。但是，該公司將從認股權證的任何現金行使中獲得收益。普通股在納斯達克資本市場上市，股票代碼爲 “ATXI”。截至2024年1月31日，Avenue Therapeutics上次公佈的普通股銷售價格爲每股0.15美元。招股說明書還包括有關證券投資所涉風險的信息，並指出美國證券交易委員會沒有批准或不批准這些證券，也沒有透露招股說明書的準確性或充分性。
有用
沒用